AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Scienture Receives Patent Approval for REZENOPY™ Nasal Spray, Strengthening IP Protection and Commercial Strategy
ByAinvest
Wednesday, Jan 14, 2026 8:07 am ET1min read
SCNX--
Scienture Holdings has announced the issuance of a US patent covering its REZENOPYTM naloxone HCl nasal spray, the highest dosage approved by the FDA for life-saving opioid overdose treatment. The patent, with an expiry date of February 5, 2041, adds intellectual property protection to the product's US commercialization. Scienture entered into a collaboration with Summit Biosciences in March 2025 for exclusive US commercialization rights. REZENOPYTM received FDA approval in April 2024 and the US naloxone market is valued at approximately $154 million annually.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet